John Mascarenhas

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. doi request reprint Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis
    John Mascarenhas
    Division of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Cancer Res 18:3008-14. 2012
  2. doi request reprint A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
    John Mascarenhas
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY Electronic address
    Clin Lymphoma Myeloma Leuk 16:S124-9. 2016
  3. pmc Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
    John O Mascarenhas
    The Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Haematologica 102:327-335. 2017
  4. doi request reprint A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    John Mascarenhas
    Tisch Cancer Institute, Division of Hemato and Oncologylogy, Icahn School of Medicine at Mount Sinai, New York, NY, United States Electronic address
    Leuk Res 53:13-19. 2017
  5. ncbi request reprint Paraneoplastic orthostatic hypotension associated with acute myeloid leukemia
    S Lee
    Department of Medicine, Elmhurst Hospital Center, Icahn School of Medicine at Mount Sinai, Elmhurst, New York, USA
    Eur Rev Med Pharmacol Sci 19:2934-7. 2015
  6. doi request reprint Rationale for combination therapy in myelofibrosis
    John Mascarenhas
    Myeloproliferative Disorder Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY, USA Electronic address
    Best Pract Res Clin Haematol 27:197-208. 2014
  7. doi request reprint The future of JAK inhibition in myelofibrosis and beyond
    John O Mascarenhas
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Electronic address
    Blood Rev 28:189-96. 2014
  8. pmc Advances in myelofibrosis: a clinical case approach
    John O Mascarenhas
    Haematologica 98:1499-509. 2013
  9. doi request reprint A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
    John Mascarenhas
    Tisch Cancer Institute, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Blood 121:4832-7. 2013
  10. doi request reprint A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
    John Mascarenhas
    Division of Hematology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Br J Haematol 161:68-75. 2013

Collaborators

Detail Information

Publications39

  1. doi request reprint Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis
    John Mascarenhas
    Division of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Cancer Res 18:3008-14. 2012
    ....
  2. doi request reprint A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
    John Mascarenhas
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY Electronic address
    Clin Lymphoma Myeloma Leuk 16:S124-9. 2016
    ..Current JAK2 inhibitor-based combination therapy approaches are supported by preclinical investigation and are currently being tested in multicenter clinical trials. ..
  3. pmc Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
    John O Mascarenhas
    The Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Haematologica 102:327-335. 2017
    ..Non-hematologic adverse events were largely grade 1 or 2; the most common was fatigue. Treatment with INCB039110 resulted in clinically meaningful symptom relief, modest spleen volume reduction, and limited myelosuppression...
  4. doi request reprint A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    John Mascarenhas
    Tisch Cancer Institute, Division of Hemato and Oncologylogy, Icahn School of Medicine at Mount Sinai, New York, NY, United States Electronic address
    Leuk Res 53:13-19. 2017
    ..The optimal dosing of panobinostat for the treatment of MF remains somewhat ill-defined but appears to be most effective and better tolerated when administered at lower doses over a prolonged duration of therapy...
  5. ncbi request reprint Paraneoplastic orthostatic hypotension associated with acute myeloid leukemia
    S Lee
    Department of Medicine, Elmhurst Hospital Center, Icahn School of Medicine at Mount Sinai, Elmhurst, New York, USA
    Eur Rev Med Pharmacol Sci 19:2934-7. 2015
    ..Physicians should be aware of this unusual occurrence of autonomic neuropathy with AML as delay in treatment of the hematologic malignancy can lead to irreversible neurologic deficit and increased morbidity and mortality. ..
  6. doi request reprint Rationale for combination therapy in myelofibrosis
    John Mascarenhas
    Myeloproliferative Disorder Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY, USA Electronic address
    Best Pract Res Clin Haematol 27:197-208. 2014
    ..This manuscript will address the proposed goals of combination therapy approach and review the state of the art in combination experimental therapy for MF. ..
  7. doi request reprint The future of JAK inhibition in myelofibrosis and beyond
    John O Mascarenhas
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Electronic address
    Blood Rev 28:189-96. 2014
    ..This review will update the reader on the current understanding of oncogenic JAK-STAT pathway activity in the pathogenesis of myeloproliferative neoplasms and the current success and limitations of anti-JAK therapy. ..
  8. pmc Advances in myelofibrosis: a clinical case approach
    John O Mascarenhas
    Haematologica 98:1499-509. 2013
    ..Three myelofibrosis cases are included to underscore the issues in diagnosing and treating this complex disease. ..
  9. doi request reprint A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
    John Mascarenhas
    Tisch Cancer Institute, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Blood 121:4832-7. 2013
    ..This critical review of these data may allow physicians to more rationally assess the benefits that can be anticipated with the appropriate use of this therapy...
  10. doi request reprint A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
    John Mascarenhas
    Division of Hematology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Br J Haematol 161:68-75. 2013
    ..We conclude that panobinostat is a well-tolerated, clinically active treatment for MF patients, regardless of JAK2 V617F status, and most effective when given at low doses over long periods of time...
  11. pmc Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium
    John Mascarenhas
    Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA
    Leuk Res 36:1500-4. 2012
    ..We plan to validate these proposed response criteria within multi-centered clinical trials...
  12. doi request reprint Myeloproliferative neoplasms: new translational therapies
    John Mascarenhas
    Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 77:667-83. 2010
    ....
  13. doi request reprint Therapeutic options for patients with myelofibrosis in blast phase
    John Mascarenhas
    Division of Hematology Oncology, The Tisch Cancer Institute, New York, NY, USA
    Leuk Res 34:1246-9. 2010
    ..DEC is a tolerable outpatient chemotherapeutic regimen for MF-BP patients ineligible for transplant and deserves further prospective study...
  14. pmc Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells
    Min Lu
    Division of Hematology Oncology, Tisch Cancer Institute and Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Blood 120:3098-105. 2012
    ..These data suggest that treatment with low doses of both Nutlin-3 combined with Peg IFN-α 2a can target PV hematopoietic progenitor cells, eliminating the numbers of malignant hematopoietic progenitor cells...
  15. pmc Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells
    Min Lu
    Tisch Cancer Institute and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Blood 116:4284-7. 2010
    ..These data provide the rationale for combination therapy with low doses of IFNα and a BH3 mimetic for patients with PV...
  16. doi request reprint Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms
    Xiaoli Wang
    Division of Hematology and Oncology, The Myeloproliferative Disorders Program, Tisch Cancer Institute, New York, NY, USA
    Exp Hematol 37:1194-200. 2009
    ....
  17. pmc Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
    Min Lu
    Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Exp Hematol 38:472-80. 2010
    ..In this study, the cellular target by which IFNalpha affects hematopoiesis in PV patients was evaluated...
  18. doi request reprint Preferences of Patients With Myeloproliferative Neoplasms for Accepting Anxiety or Depression Treatment
    Daniel C McFarland
    Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison, NY Electronic address
    Psychosomatics 58:56-63. 2017
    ..This study examined their willingness to accept an antidepressant and their preferences for which provider (mental health professional or hematologist/oncologist) prescribes an antidepressant for the management of anxiety and depression...
  19. pmc Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation
    Camelia Iancu-Rubin
    Division of Hematology and Medical Oncology, Department of Medicine and The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Exp Hematol 40:564-74. 2012
    ....
  20. doi request reprint The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms
    Sool Yeon Cho
    Department of Medicine, Division of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Cancer Res 70:3402-10. 2010
    ....
  21. doi request reprint Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis
    Alla Keyzner
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
    Biol Blood Marrow Transplant 22:2180-2186. 2016
    ..Baseline splenomegaly did not affect transplantation outcomes. Given the particularly poor outcomes seen in the unrelated donor cohort here and elsewhere, a formal exploration of alternative hematopoietic stem cell sources is warranted...
  22. ncbi request reprint Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms
    Daniel C McFarland
    From Division of Network Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, West Harrison Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York and Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York
    J Natl Compr Canc Netw 14:1563-1570. 2016
    ..Psychological manifestations among these diseases have not been adequately described...
  23. doi request reprint Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression
    Vesna Najfeld
    Tumor Cytogenetics Laboratory, Department of Pathology, The Myeloproliferative Program, Tisch Cancer Center, The Mount Sinai School of Medicine, New York, New York, USA
    Cancer Genet 204:165-70. 2011
    ....
  24. doi request reprint An unusual case of donor-derived myelodysplastic syndrome following double-unit umbilical cord blood transplantation in acute lymphoblastic leukemia
    Ryan Cotter
    Division of Hematology Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Hematol 87:931-3. 2012
    ..Current molecular techniques, including analysis of short tandem repeats (STR) and fluorescence in situ hybridization (FISH) allowed us to firmly establish donor origin...
  25. pmc Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
    Abdallah Abou Zahr
    Division of Hematology Oncology, Mount Sinai Beth Israel, New York, NY, USA
    Haematologica 101:660-71. 2016
    ..We discuss the rationale of various anti-fibrogenic treatment strategies targeting the clonal hematopoietic stem/progenitor cell, aberrant signaling pathways, fibrogenic cytokines, and the tumor microenvironment. ..
  26. doi request reprint Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
    Nicole Carreau
    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
    Blood Rev 30:349-56. 2016
    ..This manuscript reviews known and potential implications of IO in MF and highlights the need for prospective clinical investigations of ICT with consideration in the setting of JAK2 inhibitor therapy. ..
  27. doi request reprint Contemporary approach to essential thrombocythemia and polycythemia vera
    Daniel Aruch
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
    Curr Opin Hematol 23:150-60. 2016
    ..Management of polycythemia vera and essential thrombocythemia requires understanding of the key concepts regarding diagnosis, risk stratification, and management...
  28. pmc The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
    Selcuk Sozer
    Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Blood 113:5246-9. 2009
    ....
  29. doi request reprint Psychological Manifestations of Early Childhood Adversity in the Context of Chronic Hematologic Malignancy
    Daniel C McFarland
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY DCM Electronic address
    Psychosomatics 58:46-55. 2017
    ..Myeloproliferative neoplasms (MPNs), a group of chronic hematologic malignancies, carry significant physical and psychological symptom burdens that significantly affect patients' quality of life...
  30. pmc A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells
    Xiaoli Wang
    Division of Hematology Oncology, The Tisch Cancer Institute, Department of Medicine, Myeloproliferative Disorders Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY
    Blood 127:3398-409. 2016
    ..These findings demonstrate that such specific anti-cytokine receptor antagonists represent a new class of drugs that are capable of targeting MF HSCs. ..
  31. doi request reprint Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera
    Marina Kremyanskaya
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place Box 1079, New York, NY 10029, USA
    Expert Opin Pharmacother 16:1185-94. 2015
    ..New treatment options for polycythemia vera (PV) have recently become available. This article reviews current treatment strategies for PV with a focus on anagrelide and ruxolitinib...
  32. doi request reprint Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia
    Jyoti Malhotra
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
    Clin Lymphoma Myeloma Leuk 14:31-6. 2014
    ..There are numerous case reports and reviews reporting patients with coexisting MPN and plasma-cell disease such as multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS)...
  33. doi request reprint Why does my patient have erythrocytosis?
    Marina Kremyanskaya
    Department of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1079, New York, NY 10029, USA
    Hematol Oncol Clin North Am 26:267-83, vii-viii. 2012
    ..A single recurrent point mutation in the pseudokinase domain of JAK2 molecule (JAK2(V617F)) is present in >95% of patients with PV. The goal of therapy in PV is to normalize blood counts to minimize the risk of thrombotic events...
  34. doi request reprint Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions
    Sheena Bhalla
    Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
    Clin Lymphoma Myeloma Leuk 16:488-494. 2016
    ....
  35. doi request reprint Systemic Mastocytosis: Clinical Update and Future Directions
    Douglas Tremblay
    Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
    Clin Lymphoma Myeloma Leuk 15:728-38. 2015
    ..Here we seek to familiarize clinicians with this orphan disease and review current and future treatment approaches. ..
  36. pmc MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
    Damiano Rondelli
    University of Illinois Hospital and Health Sciences System and University of Illinois Cancer Center, Chicago, IL Myeloproliferative Disorders Research Consortium, Mount Sinai School of Medicine, New York, NY
    Blood 124:1183-91. 2014
    ..This trial was registered at www.clinicaltrials.gov as #NCT00572897. ..
  37. doi request reprint Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm
    Raajit Rampal
    aLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center bTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
    Curr Opin Hematol 21:65-71. 2014
    ..Here, we discuss the recent identification of risk factors for leukemic transformation, elucidate mechanisms contributing to leukemic transformation, as well as highlight the development of new treatment strategies...
  38. doi request reprint Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders
    Takefumi Ishii
    Division of Hematology Oncology, Tisch Cancer Institute and Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Blood 113:5942-50. 2009
    ..These data demonstrate that functional abnormalities of MPD MCs probably lead to pruritogenesis in patients with MPDs. These studies provide cellular and molecular targets for the development of antipruritus drugs for patients with MPDs...